Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,471.00    11.00 (0.75%)
Bid:
1,475.00
Ask:
1,477.00
Spread: 2.00 (0.136%)
Market Cap: £3.13b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Dividend Declaration

13 May 2011 14:04

RNS Number : 5844G
Hikma Pharmaceuticals Plc
13 May 2011
 



  

Hikma Pharmaceuticals PLC

Final Dividend for 2010

LONDON, 13 May 2011 - Hikma Pharmaceuticals PLC ("the Company") advises that at its Annual General Meeting of shareholders, held on 12 May 2011, the final dividend of 7.5 cents per share was approved by shareholders. The dividend will be paid on 26 May 2011 to shareholders on the register on 15 April 2011.

Shareholders who have elected to receive their dividend in Pounds Sterling will receive approximately 4.6 pence per Ordinary Share (exchange rate US$1.6278 to GBP£1).

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Henry Knowles

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

Investor Relations Director

 

+44 20 7399 2670

 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders was $99 million (2009 $78 million).

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DIVAJMJTMBMBBJB
Date   Source Headline
15th Apr 201912:23 pmRNSAnnual Financial Report
1st Apr 20195:42 pmRNSTotal Voting Rights
1st Apr 20195:11 pmRNSBlock listing Interim Review
18th Mar 20193:09 pmRNSDirector/PDMR Shareholding
15th Mar 201910:32 amRNSDirector/PDMR Shareholding
14th Mar 20199:14 amRNSDirector/PDMR Shareholding
13th Mar 20191:50 pmRNSDirector/PDMR Shareholding
13th Mar 20191:49 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSFinal Results
12th Mar 20197:00 amRNSDirectorate Change
1st Mar 20194:51 pmRNSTotal Voting Rights
28th Feb 20199:00 amRNSHikma establishes partnership with Melinta in MENA
27th Feb 20191:26 pmRNSBlock listing Interim Review
26th Feb 201911:08 amRNSNotice of Results
11th Feb 201910:11 amRNSDirector/PDMR Shareholding
1st Feb 20193:43 pmRNSTotal Voting Rights
29th Jan 20199:00 amRNSHikma launches Mitomycin for Injection
3rd Jan 20199:00 amRNSHikma announces agreement with Sciecure Pharma
19th Dec 20186:30 pmRNSShire
10th Dec 20189:00 amRNSHikma launches Clobazam
3rd Dec 201810:30 amRNSTotal Voting Rights
27th Nov 20189:00 amRNSHikma announces injectable licensing agreement
19th Nov 20189:00 amRNSHikma launches Triazolam Tablets
13th Nov 201811:15 amRNSHolding(s) in Company
8th Nov 20189:44 amRNSHikma announces agreement with Vectura
8th Nov 20187:00 amRNSHikma announces agreement with Vectura
8th Nov 20187:00 amRNSTrading Statement
1st Nov 201812:39 pmRNSTotal Voting Rights
16th Oct 20184:30 pmRNSBlock listing Interim Review
1st Oct 201810:53 amRNSTotal Voting Rights
1st Oct 201810:23 amRNSHolding(s) in Company
3rd Sep 201811:05 amRNSTotal Voting Rights
30th Aug 20189:58 amRNSHolding(s) in Company
28th Aug 201812:45 pmRNSHolding(s) in Company
22nd Aug 20189:41 amRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSHalf-year Report
23rd Jul 20189:00 amRNSNotice of Results
9th Jul 20189:00 amRNSHikma enters licensing partnership with Perrigo
2nd Jul 20184:56 pmRNSTotal Voting Rights
15th Jun 20183:24 pmRNSDirector/PDMR Shareholding
8th Jun 201811:50 amRNSDirector/PDMR Shareholding
4th Jun 201810:29 amRNSDirector/PDMR Shareholding
4th Jun 20189:00 amRNSHikma appoints Chief Transformation Officer
1st Jun 201811:34 amRNSTotal Voting Rights
30th May 20183:20 pmRNSDirector/PDMR Shareholding
30th May 20189:00 amRNSHikma launches Methylergonovine Maleate Tablets
23rd May 201810:20 amRNSDirector/PDMR Shareholding
18th May 20181:01 pmRNSAGM Results
18th May 20187:00 amRNSTrading Statement
17th May 20181:45 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.